Clinical Report: Impact of Peer Feedback on Antibiotic Prescribing Practices
Overview
This quality improvement study evaluates the effect of peer feedback on hospitalists' antibiotic prescribing practices, specifically targeting excessive empiric antibiotic use. The implementation of individualized feedback reports was associated with improved adherence to antibiotic stewardship guidelines.
Background
Inappropriate antibiotic prescribing contributes significantly to antibiotic resistance and adverse patient outcomes, including Clostridioides difficile infections. Effective antibiotic stewardship is crucial in inpatient settings, where prescribing practices are often complex and influenced by various patient factors. This study addresses the need for more granular metrics and targeted interventions to optimize antibiotic use among hospitalists.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
Peer feedback reports were developed to provide hospitalists with individualized prescribing data.
The intervention included educational sessions on antibiotic de-escalation and evidence-based prescribing.
Hospitalists received bimonthly email reports detailing their prescribing practices compared to expected norms.
Observed-to-expected ratios were calculated to adjust for patient risk factors such as sepsis and end-stage kidney disease.
The initiative was well-received and aligned with existing antibiotic stewardship efforts.
Clinical Implications
Implementing peer feedback mechanisms can enhance antibiotic stewardship efforts among hospitalists, potentially leading to reduced inappropriate prescribing. Continuous education and timely feedback are essential components of successful interventions in this area.
Conclusion
The study demonstrates that structured peer feedback can positively influence antibiotic prescribing practices among hospitalists, contributing to improved patient safety and antibiotic stewardship.
by Lucy S. Witt, Radhika Prakash-Asrani, K. Ashley Jones, C. Christina Mehta, Zanthia Wiley, Jesse T. Jacob, Hasan F. Shabbir, Julianne Gent, Chad Robichaux, Jessica Howard-Anderson, Sujit Suchindran, Julia E. Szymczak, Raymund B. Dantes, Scott K. Fridkin
Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.
